GSK-2862277

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameGSK-2862277
Drug Alias NameGSK-28622772862277
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionTumor necrosis factor receptor superfamily member 1A inhibitors
TargetsTumor necrosis factor receptor superfamily member 1A
Therapy Area/IndicationsRespiration DisordersRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsRespiration DisordersRespiratory Distress Syndrome, Adult

Other Information

ATC CodeN/A
Related LinksN/A